Triple-Negative Breast Cancer

Speaker: Veronique Dieras

V. Dieras reports that there is no changes in practice after presentation of studies in triple-negative breast cancer at ASCO 2015. She elaborates the results of adjuvant phase III TITAN study that investigated a role of ixabepilone, and phase III BEACON study with etirinotecan pegol in advance setting. After that she explores the biology of disease, in particular AR and PD-L1 expression, as well as BRCA1 status that open a possibility for studying new agents.

Discussion Points

  • TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC). (Abstract #1000)
  • Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician's Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study (Abstract #1001)
  • Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC). (Abstarct #1005)
  • Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). (Abstract #1003)